Introduction
============

Natural transformation, a dominant force in the evolution of bacteria, is responsible for gene exchange and the acquisition of new DNA sequences, and is an important tool in genetic engineering. Most members of the Mitis group of streptococci are naturally competent for genetic transformation and produce competence pheromones, also known as competence stimulating peptides (CSPs), recognized by cognate surface receptors ([@B14]). Competence development is most studied in *S. pneumoniae*, also a member of the Mitis group. In this model organism, competence is characterized by two main processes: (1) quorum-sensing (QS) and (2) expression of effectors that allow DNA binding, uptake, and integration into the bacterial genome ([@B5]; [@B23]). The QS pathway launches the competence development cascade: first, *comC* is activated, and its activation leads to the transcription and translation of the gene into a pro-peptide before it is cleaved and exported as the CSP by an ABC transporter, ComAB ([@B14]). Once CSP reaches a threshold concentration in the extracellular environment, it binds to its membrane receptor histidine kinase ComD, resulting in the phosphorylation of the response regulator ComE. ComE phosphorylation activates expression of the alternative sigma factor σ^X^ ([@B22]; [@B5]) in addition to ∼20 early genes (**Figure [1](#F1){ref-type="fig"}**). The σ^X^ regulon includes in total 27 to 30 pan-streptococcal core genes ([@B17]), involved in exogenous DNA uptake, processing, and recombination. Environmental factors are also known to have an important impact on the development of competence and in the magnitude of the response to CSPs. However, in contrast to the molecular mechanisms involved in the CSP response and production that have been described in great detail, such environmental factors are still poorly defined ([@B15]). Notably, while conditions defined for some closely related species can be used as a start point for transformation, optimal levels of competence often require a series of optimization strategies, with an outcome that is not always predictable. In *Streptococcus pyogenes*, for instance, despite a series of optimization approaches, competence has only been demonstrated in the presence of epithelial cells and at levels that do not surpass 0.0001% ([@B25]).

![**Competence in the Mitis group of streptococci**. The CSP pheromone produced by streptococci, upon reaching a threshold concentration binds to the histidine kinase ComD, leading to phosphorylation of the response regulator ComE. ComE-P activates a positive feedback loop by inducing the expression of *comCDE*, and also induces the expression of *sigX*, which encodes the alternative sigma factor σ^X^. σ^X^ binds to the RNA polymerase (RNAP), to activate the expression of 27 to 30 panstreptococcal competence genes responsible among other functions for DNA uptake and recombination, as well as DNA scavenging via fratricide. Optimization of conditions for transformation of the Mitis group has been mostly studied in *S. pneumoniae*. For other species in this group, conditions for optimal competence are generally unknown.](fmicb-07-01009-g001){#F1}

The human oral commensal *Streptococcus mitis*, a member of the Mitis group of streptococci, colonizes all surfaces of the oral cavity including teeth, tongue and mucosal surfaces, in addition to the tonsils and nasopharynx ([@B31]). *S. mitis* and *S. pneumoniae* -- one of the most important human pathogens --, share \>80% of their genes. Being genetically very similar, their differences in pathogenic potential are striking ([@B20]). In comparison to *S. pneumoniae* and their common ancestor, evolutionary analyses suggest that loss of virulence determinants in *S. mitis* may be the reason for the decrease in its pathogenicity ([@B19]). In contrast with *S. pneumoniae*, in which most of the strains use one of two pheromones, in *S. mitis* almost each strain has its own CSP ([@B19]). Despite the high interest in understanding *S. mitis* behavior, low transformation yields and challenges in genetic manipulation of this species, reflected in the literature for three decades, have probably hampered advances in the field ([@B11]; [@B35]; [@B1]; [@B27]; [@B8]; [@B36]; [@B43]). Prior to the introduction of synthetic CSPs for transformation, Gaustad ([@B11]) first reported *S. mitis* transformation efficiencies of around 0.0001%. This level was further shown to increase to 0.001% with the use of synthetic CSP by [@B1]. Difficulties in transforming *S. mitis* were later also reported for B6, the first genome sequenced strain ([@B7]). For the type strain, [@B8] reported failures in obtaining any transformants at all. We have been able to transform the type strain previously ([@B36]), but only at low efficiency. Considering the multiple fields in which *S. mitis* has been studied, the development of a highly efficient method for *S. mitis* genetic manipulation through natural transformation is of great interest and value.

We recently described a markerless method for genome editing without introduction of selective markers that is applicable for streptococci with high transformation efficiencies ([@B28]). Overcoming the challenges of low transformation efficiencies in *S. mitis* would thus not only facilitate the genetic manipulation of this organism using marker selection methods, but it would also allow the use of direct markerless genome editing approaches in *S. mitis* functional investigations. The aim of this study was to identify optimal conditions for natural genetic transformation in *Streptococcus mitis*, and to illustrate its application as a genome editing resource. We now report the development of a method for high efficiency transformation of the type strain, which is also applicable for strain SK321. Further, we demonstrate its use in direct genome editing.

Materials and Methods {#s1}
=====================

Bacterial Strains and Media
---------------------------

All strains of *S. mitis* used are listed in **Table [1](#T1){ref-type="table"}**. Streptococci were stored at -80°C in Todd Hewitt Broth (THB, Becton Dickinson and Company, Le Pont de Claix, France) or Tryptic Soy Broth (TSB, Soybean-Casein Digest medium, BactoTM) supplemented with 30% glycerol. Pre-cultures used in the experiments described below were made from fresh liquid cultures incubated at 37°C in a 5% CO~2~-supplemented atmosphere and grown until the cultures reached an absorbance at 600 nm (optical density at 600 nm \[OD~600~\]; Biophotometer; Eppendorf) of 0.5, before storage at -80°C in 15% glycerol. For transformation assays, Tryptic Soy Broth (TSB, Soybean-Casein Digest medium, BactoTM), THB supplemented with 5% of horse serum (THB-HS) ([@B33]), semi-defined media C+Y~Y\ B~ ([@B38]) or C+Y ([@B26]) were used. For plating, blood agar base No. 2 (Oxoid, Hampshire, England) supplemented with 5% defibrinated sheep blood (TCS Biosciences Ltd., Buckingham, UK) was used. Final concentrations of selective levels of antibiotics were 500 μg mL^-1^ kanamycin, 10 μg mL^-1^ erythromycin, and 200 μg mL^-1^ spectinomycin.

###### 

Strains, synthetic peptides and primers used in this study.

  Strains                                    Description^a^                                                                                      Source or characteristics
  ------------------------------------------ --------------------------------------------------------------------------------------------------- ----------------------------
  *Streptococcus mitis* CCUG 31611^T^        *S. mitis* biovar 1 type strain, corresponds to NCTC 12261^T^; encapsulated, transformable strain   CCUG
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* NCTC 8033 (SK321)               *S. mitis* strain isolated from the oral cavity                                                     NCTC; ([@B19])
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* CCUG 62644 (SK575)              *S. mitis* strain isolated from blood; Erm^R^                                                       CCUG; ([@B19])
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* CCUG 62641 (SK579)              *S. mitis* strain isolated from blood                                                               CCUG
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* CCUG 62642 (SK616)              *S. mitis* strain isolated from blood                                                               CCUG; ([@B19])
                                                                                                                                                 
                                                                                                                                                 
  MI009                                      CCUG 31611, but Δ*srtA*::*erm*; Erm^R^                                                              This study
                                                                                                                                                 
                                                                                                                                                 
  MI055                                      CCUG 31611, but p*~sigX~* luc::*spc*; Spc^R^                                                        This study
                                                                                                                                                 
                                                                                                                                                 
  MI074                                      CCUG 31611, but Δ*SM12261_0092*::*kan*; Kan^R^                                                      This study
                                                                                                                                                 
                                                                                                                                                 
  MI091                                      CCUG 31611, but Δ*shp*                                                                              This study
                                                                                                                                                 
                                                                                                                                                 
  MI092                                      SK321, but p*~sigX~* luc::*spc*; Spc^R^                                                             This study
                                                                                                                                                 
                                                                                                                                                 
  **Competence Stimulating Peptide (CSP)**   **Sequence**                                                                                        
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* CCUG 31611                      EIRQTHNIFFNFFKRR                                                                                    GenScript
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* SK321                           ESRLPKIRFDFIFPRKK                                                                                   GenScript
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* SK575                           EMRKMNEKSFNFF                                                                                       GenScript
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* SK579                           EIRKSNSALVNFFK                                                                                      GenScript
                                                                                                                                                 
                                                                                                                                                 
  *S. mitis* SK616                           EMRRIDKIFINFLKRR                                                                                    GenScript
                                                                                                                                                 
                                                                                                                                                 
  **Primers**                                **Sequence (5′ to 3′)**                                                                             
                                                                                                                                                 
                                                                                                                                                 
  FP001^b^                                   [ggcgcgcc]{.ul}GTTTGATTTTTAATG                                                                      Kan^R^ cassette
                                                                                                                                                 
                                                                                                                                                 
  FP015^b^                                   [ggcgcgcc]{.ul}CCGGGCCCAAAATTTGTTTGAT                                                               Erm^R^ cassette
                                                                                                                                                 
                                                                                                                                                 
  FP016^c^                                   [ggccggcc]{.ul}AGTCGGCAGCGACTCATAGAAT                                                               Erm^R^ cassette
                                                                                                                                                 
                                                                                                                                                 
  FP068^c^                                   a[ggccggcc]{.ul}TAGGTACTAAAACAATTCATCCAGTA                                                          Km^R^ cassette
                                                                                                                                                 
                                                                                                                                                 
  FP411                                      AGCCGTTCGTGGTATGAGTC                                                                                MI009 mutant construction
                                                                                                                                                 
                                                                                                                                                 
  FP412^b^                                   [ggcgcgcc]{.ul}TTTGATACCTGGCTGACTTGG                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP413^c^                                   [ggccggcc]{.ul}AGATCGCGTTGATGAGATTGA                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP414                                      CTCAGCCGTTTTTCTCCAAG                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP770^d^                                   [aaagctagc]{.ul}AGCTGCTTTAGTCGCTGCTC                                                                pFW5-*luc*
                                                                                                                                                 
                                                                                                                                                 
  FP771^e^                                   [aaaggatcc]{.ul}CAATCCCCTGGACTTCTTCA                                                                pFW5-*luc*
                                                                                                                                                 
                                                                                                                                                 
  FP829^c^                                   [ggccggcc]{.ul}TTTTTGCTGTAAACTAAGGAGTAGAGA                                                          MI074 mutant construction
                                                                                                                                                 
                                                                                                                                                 
  FP830                                      CGACTTCGATCTTTTAGTTGATG                                                                             
                                                                                                                                                 
                                                                                                                                                 
  FP831                                      CCCGTTTTCCCAACAAAAA                                                                                 
                                                                                                                                                 
                                                                                                                                                 
  FP832^b^                                   [ggcgcgcc]{.ul}TTTTCTGTACACCTCATTTCCTTT                                                             
                                                                                                                                                 
                                                                                                                                                 
  FP914                                      TCTCGCGGAAGATAAAGTCG                                                                                MI009 mutant amplification
                                                                                                                                                 
                                                                                                                                                 
  FP915                                      GGGTTAGCAGCAACAAGGAA                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1163                                     CATCTTGATAGCGTGGCTCA                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1164                                     GAAGTCTAAATATGAAGAAGGTGTACACCTAAGTCT                                                                MI091mutant construction
                                                                                                                                                 
                                                                                                                                                 
  FP1165                                     AGACTTAGGTGTACACCTTCTTCATATTTAGACTTC                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1166                                     TTGAATTGAGACGGATTGGA                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1167                                     GCTGAGTTCCTCCAAGCTGT                                                                                MI009 mutant amplification
                                                                                                                                                 
                                                                                                                                                 
  FP1168                                     ATCCAGAAACGACCGACAAG                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1169                                     TCTTTCATCGTGTCCTCCAA                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1170                                     TGATTCTCCCCGTTCAAATC                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1171                                     AAACATTTTATCCACCGACAA                                                                               
                                                                                                                                                 
                                                                                                                                                 
  FP1172                                     TTGCACCAAGTTAGCGAATG                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1242                                     CTTGAGCTGGGCTTCGTAGT                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1243                                     ACAGGGGATGTCATGGGTAA                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1244                                     CTGCTACGTTTGCAAGGTCA                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1245                                     ATGAACGTGAACCCTTGGTC                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1248                                     CAGCATGCAGTTGCAAAGTT                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1249                                     CCCGAACGTGTTTCTCAAAT                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1250                                     CTCAGCCGTTTTTCTCCAAG                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1251                                     AGTATGGCCGTATTGCCAAG                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1280                                     GCACCTGTATCACGAAGCAA                                                                                
                                                                                                                                                 
                                                                                                                                                 
  FP1281                                     TGCTGAAGCACAAGCTGAGT                                                                                

a

Kan, kanamycin; Erm, erythromycin; Spc, spectinomycin.

b

AscI restriction site underlined.

c

FseI restriction site underlined.

d

BamHI restriction site underlined.

e

NheI restriction site underlined

.

Competence-Stimulating Peptide
------------------------------

Stock solutions of the lyophilized CSPs (**Table [1](#T1){ref-type="table"}**) were prepared by re-suspending the material in distilled water to a concentration of 10 mM, and storing it at -20°C. Working solutions of 100 μM were aliquoted and stored at -20°C.

Luciferase Reporter Assays
--------------------------

Culture stocks of the P*sigX*-luciferase strain MI055 and MI092 at OD~600~ 0.5 were diluted in the presence or absence of CSP, and luminescence was monitored as described previously ([@B28]).

Construction of Mutants with Antibiotic Markers
-----------------------------------------------

All primers used for marker constructions are listed in **Table [1](#T1){ref-type="table"}**. For construction of the *S. mitis* Δ*srtA* (MI009) and Δ*SM12261_0092* (MI074) mutants, the standard PCR ligation mutagenesis strategy was employed ([@B21]), with minor modifications ([@B36]). The *srtA* flanking regions were amplified using primer pairs FP411--FP412 and FP413--FP414. The Δ*SM12261_0092* flanking regions were amplified with the primer pairs FP829--FP830 and FP831--FP832. The erythromycin and kanamycin resistance cassettes (Erm^R^, Km^R^) ([@B4]; [@B39]) were amplified using the primer pairs FP015--FP016 and FP001--FP068, respectively. Ligation and purification of the PCR products were performed using T4 DNA ligase (Fermentas) and the QIAquick PCR purification kit (Qiagen), respectively. The resultant amplicons were used for transformation of *S. mitis* as described below. Correct insertion of erythromycin or kanamycin markers in the deleted region was verified by PCR amplification of the chromosomal DNA extracted from each mutant, using primer pairs complementary to sequences within the antibiotic cassette sequence in combination with primers in regions up and downstream the insertion of the antibiotic cassette. To construct MI055, the luciferase reporter for *sigX*, the primer pair FP770--FP771 was used to amplify the specific promoter region from the *S. mitis* type strain. Following restriction with *Bam*HI and *Nhe*I, the amplicon was ligated to pFW5-*luc* (Spec^R^) and cloned into *Escherichia coli* as previously described ([@B18]). A plasmid with the correct insert was further purified and transformed into the *S. mitis* type strain, where it was incorporated in the chromosome by single cross-over recombination.

Transformation Assays
---------------------

For construction of marker insertions, the following protocol was used. Pre-cultures of the *S. mitis* type strain at OD~600~ 0.5 were diluted 1:10 in TSB and liquid cultures were grown at 37°C, 5% CO~2~ for 15 min. Then, 250 nM CSP was added, together with the PCR constructs or donor plasmids. Cultures were incubated under aerobic conditions at 37°C for 4 h. Transformants were selected on blood agar plates supplemented with the appropriate antibiotics by 24 h of incubation at 37°C, 5% CO~2~.

For optimization steps, different protocols were used as described in the results section.

Preparation of Plasmids
-----------------------

The replicative shuttle plasmid pVA838 ([@B24]) and the non-replicative plasmid pFW5-*luc* ([@B34]) were isolated from *E. coli* using the QIAprep Spin Miniprep kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's recommendations.

Preparation of Genomic Donor DNA
--------------------------------

Genomic donor DNA was extracted from strains according to the CTAB method previously described ([@B32]).

Preparation of Donor DNA Amplicons
----------------------------------

Primers used for amplification of donor DNA from existing mutants are listed in **Table [1](#T1){ref-type="table"}** and corresponding amplicons are described in **Table [2](#T2){ref-type="table"}**. PCR conditions and primers can be found elsewhere ([@B28]).

###### 

Donor DNA amplicons.

  Amplicon   Primers, amplicon size, marker, and template        Source
  ---------- --------------------------------------------------- ------------
  aRJ19      FP1167/FP1168 -- 5.2 kb -- Markerless, from MI091   This study
  aRJ20      FP914/FP915 -- 6.9 kb -- Erm^R^, from MI009         This study
  aRJ21      FP1163/FP1166 -- 6.9 kb -- Kan^R^, from MI074       This study
  aRJ22      FP1250/FP1251 -- 1.9 kb -- Erm^R^, from MI009       This study
  aRJ23      FP1248/FP1249 -- 3.0 kb -- Erm^R^, from MI009       This study
  aRJ24      FP1280/FP1281 -- 3.9 kb -- Erm^R^, from MI009       This study
  aRJ25      FP1244/FP1245 -- 4.9 kb -- Erm^R^, from MI009       This study
  aRJ26      FP1242/FP1243 -- 5.9 kb -- Erm^R^, from MI009       This study

Markerless Mutant Construction
------------------------------

To construct the markerless mutant MI091, with deletion of a putative pheromone gene (*shp*) located between Δ*SM12261_0093* and Δ*SM12261_0094*, two flanking fragments of 3 kb were amplified from *S. mitis* type strain with the primer pairs FP1163--FP1164 and FP1165--FP1166. Overlapping sequences were used for fusion of the two PCR products, in a ligase-free PCR reaction that used less than 50 ng of each of the two amplified sequences and the nested primers FP1167 and FP1168, to produce an amplicon of 5224 bp. After transformation of competent cells of the *S. mitis* type strain, as described in the optimized protocol, colonies from blood plates were screened by PCR, and re-screened to identify a clone containing the correct deletion.

Detection of Markerless Mutation through Colony Genotyping Assay
----------------------------------------------------------------

Colonies on non-selective plates were screened by PCR using primers specific, respectively, for the donor and recipient alleles at targeted loci, as previously described ([@B28]).

Statistical Analysis
--------------------

Two-way ANOVA with multiple measures followed by Tukey's test was used to analyze differences between groups. Student's *t*-test was used to compare two independent samples. A *p* \< 0.05 was considered statistically significant.

Results and Discussion
======================

Semi-Defined Medium Enriched with Bovine Serum Albumin Supports High CSP Signaling in *S. mitis*
------------------------------------------------------------------------------------------------

Previous protocols for transformation of *S. mitis* have suggested the use of a rich medium (Todd Hewitt Broth or Tryptic Soya Broth) for culture growth and transformation ([@B12]; [@B33]). However, for some species of streptococci, such as *Streptococcus thermophilus*, transformation is mostly restricted to growth in defined media with restricted peptide contents ([@B10]). Thus, when looking for alternatives to increase *S. mitis* low transformation efficiency, ranging from 0.001 to 0.5%, we thought to compare competence in TSB with two semi-defined media: C+Y, a medium often used for transformation of *S. pneumoniae*, and C+Y~Y\ B~, a medium derived from C+Y, with an increased concentration of yeast extract and additional bovine serum albumin, permissive for development of spontaneous competence in *S. pneumoniae* ([@B38]). The *sigX* expression was significantly higher in the culture in C+Y~Y\ B~ medium than in C+Y or TSB, suggesting that this medium might also allow increased rates of transformation in *S. mitis* (**Figures [2A--C](#F2){ref-type="fig"}**).

![**Effect of growth medium and dilution ratios on CSP-induced *sigX* expression profiles**. **(A--C)** The *sigX* reporter type strain (MI055; p*~sigX~* luc) was grown in 200 μL of TSB, C+Y, or C+Y~Y\ B~ in a 96-well plate in air at 37°C with 150 nM CSP. ^∗^ Significant statistical difference in C+Y~Y\ B~ when compared to C+Y and TSB (*p* \< 0.05). **(D--F)** Comparison of *sigX* expression profiles and culture growth in pre-culture dilution ratios of 1:10, 1:50, or 1:100. Strain MI055 (*p~sigX~* luc) was grown in 200 μL volumes of C+Y~Y\ B~ in a 96-well plate in air at 37°C with 150 nM CSP. ^∗^ Significant differences on *sigX* expression comparing 1:10 and 1:50 to 1:100 (*p* \< 0.05). For media comparison, pre-cultures were prepared in TSB and on the day of experiment they were centrifuged and re-suspended 1:100 in fresh medium -- TSB, C+Y or C+Y~Y\ B~. For all figures, *sigX* expression, presented as relative luminescence units (RLU), and culture optical density (OD) were measured periodically. The results are averages from 3 replicates and representative of three independent experiments. Error bars represent standard error of the mean. Differences in *sigX* expression among media and dilutions rates were analyzed by two-way ANOVA.](fmicb-07-01009-g002){#F2}

Dilution Rate of Cultures Influences the CSP Response
-----------------------------------------------------

In *S. pneumoniae*, the basic *in vitro* requirements for high competence to appear include (1) a culture of cells that have not recently been competent since the refractory period, (2) a culture at the early exponential phase of growth, as planktonic cells close to the stationary phase respond poorly to CSP, and (3) exposure to a culture medium conducive to development of competence ([@B41]; [@B42]; [@B29]). The results in **Figure [2](#F2){ref-type="fig"}** showing background levels of *sigX* expression at the start of the experiments indicate that the cells were not in a competent state, in line with the first requirement for competence in *S. pneumoniae*. As to the second and third requirements, we observed that expression of *sigX* in *S. mitis* is activated early in all three tested media and it is shut off after approximately 30 more minutes (**Figure [2](#F2){ref-type="fig"}**), and experiments with the addition of CSP to cultures entering stationary phase show a transformation efficiency below 0,001% (data not shown). Our next step was to investigate whether the dilution rate of the pre-cultures into the fresh medium would affect the *S. mitis* CSP response. Although the time to achieve optimal competence levels was not markedly affected, cells from cultures diluted in a 1:100 ratio presented a somewhat (50%) higher *sigX* signaling compared to cells diluted 1:50 or 1:10 (**Figures [2D--F](#F2){ref-type="fig"}**). Thus, this ratio was used in the further optimization steps described below.

*S. mitis* Competence for Genetic Transformation is Transient
-------------------------------------------------------------

To explore the kinetics of transformation in *S. mitis*, we performed a time-course study evaluating *sigX* expression employing luciferase reporter assays and monitoring transformation efficiency throughout 240 min of incubation of an inoculum starting with an OD~600~ of 0.04. *sigX* expression increased rapidly after the addition of the synthetic peptide, with its peak occurring at 30 min and decreasing gradually until disappearing at 240 min (**Figure [3](#F3){ref-type="fig"}**). Following a similar pattern, transformation efficiency reached its highest value (12%) after 45 min of incubation with the competence factor, followed by a gradual decrease. Our results demonstrate that competence for genetic transformation in *S. mitis* type strain is transient, as it is in its close relative *S. pneumoniae* ([@B13]; [@B2]).

![**Responses of the *Streptococcus mitis sigX* reporter in the type strain to CSP**. A pre-culture of MI055 at OD~600~ 0.5 was diluted 1:100 in C+Y~Y\ B~ and grown until OD~600~ 0.04 at 37°C in 5% CO~2.~ At time~0,~ the lag phase cell culture (OD~600~ 0.039) was treated with 300 nM CSP and distributed into 200 μL aliquots that were further exposed to 150 ng mL^-1^ amplicon donor DNA of 7 kb (aRJ20) at different time points. 20 U mL^-1^ DNase I were added after 30 min of exposure to DNA and the culture was incubated in air at 37°C for additional 30 min. The % of CFU containing Erm^R^ transformants was determined by plating on blood plates with or without 20 μg mL^-1^ erythromycin. **(A)** Growth curves with and without CSP, measured as OD~600~. **(B)** Induction of *sigX* and transformation. The results are average from 3 triplicates and representative of two independent experiments. Error bars represent the standard error of the mean.](fmicb-07-01009-g003){#F3}

Effect of CSP Concentration on Growth and Transformation
--------------------------------------------------------

In *S. pneumoniae*, cells that are growing rapidly in a competence permissive medium, can be induced to competence by a low (45 nM CSP-1) level of the CSP ([@B13]). However, a minority of the cells that do not develop competence are lysed by the competent cells, resulting in DNA release ([@B37]). This fact, along with the previously described CSP-derived stress ([@B30]), may explain the detrimental effect of CSP on *S. pneumoniae* growth rates. Nonetheless, neither the concentration of synthetic CSP for optimal transformation of *S. mitis* nor the effects of the peptide on growth are known. We investigated the transformation efficiency and growth of the *S. mitis* type strain under CSP concentrations ranging from 10 to 510 nM (**Figure [4](#F4){ref-type="fig"}**). Transformation efficiency was stimulated by a concentration as low as 25 nM, reaching saturation at approximately 210 nM. The final culture density was only slightly affected in the presence of CSP.

![**Effect of CSP concentration on transformation efficiency and culture density**. *S. mitis* type strain pre-culture at OD~600~ 0.5 was diluted 1:100 in C+Y~Y\ B~ and grown until OD~600~ 0.04 at 37°C in 5% CO~2~. Following, 500 μL aliquots were exposed to 150 ng mL^-1^of the 7 kb amplicon donor (aRJ21) and CSP concentrations varying from 0 to 507 nM. Cultures were further incubated in closed tubes for 4 h at 37°C in air atmosphere. Optical density of the cultures was measured at the time of plating. The % of CFU containing Kan^R^ transformants was determined by plating on blood plates with or without 500 μg mL^-1^ kanamycin. The results are averages from 3 replicates and representative of three independent experiments. Error bars represent standard error of the mean.](fmicb-07-01009-g004){#F4}

Transformation Efficiency Depends on Amount, Source, and Size of Donor DNA
--------------------------------------------------------------------------

The complexity of the donor DNA is a crucial factor for the yield of recombinants ([@B28]). A 7 kb PCR product is, for instance, ∼300-fold less complex than chromosomal DNA from the same genomic template. Thus, chromosomal DNA carries irrelevant genetic material that will compete for incorporation with the fragment of interest. To test this effect in *S. mitis* transformation, we compared chromosomal DNA and a large (7 kb) unique donor DNA amplicon (aRJ20), embodying the same antibiotic resistance insert. **Figure [5](#F5){ref-type="fig"}** shows that maximum transformation yields were achieved with 6 μg mL^-1^ of chromosomal DNA and 150 ng mL^-1^ amplicon, respectively. These values were close to those previously found in other streptococci, in which saturated concentrations are in the range of 1 to 4 μg mL^-1^ of chromosomal DNA, and 75--100 ng mL^-1^ of amplicon donor DNA ([@B13]; [@B2]; [@B16]; [@B28]). As expected, the two sources of DNA tested varied in efficiency, with transformation achieving 80-fold higher values with the amplicon than with the chromosomal DNA (**Figure [5](#F5){ref-type="fig"}**).

![**Transformation as a function of donor DNA type and concentration**. *S. mitis* type strain pre-culture at OD~600~ 0.5 was diluted 1:100 in C+Y~Y\ B~ and grown until OD~600~ 0.04 at 37°C 5% in CO~2~. **(A)** 200 μL aliquots were exposed to 300 nM of CSP and chromosomal DNA concentrations (from strain MI009) ranging from 1,38 to 30 μg mL^-1^. Cells were further incubated in closed tubes for 3 h at 37°C in air atmosphere. **(B)** 200 μL aliquots were exposed to 300 nM of CSP and 7 kb amplicon (aRJ20) concentrations varying from 32 to 173 ng mL^-1^. Cells were further incubated in closed tubes for 3 h at 37°C in air atmosphere. The % of CFU containing Erm^R^ transformants was determined by plating on blood plates with and without Erm. The results are averages from 3 replicates and representative of three independent experiments. Error bars represent standard error of the mean.](fmicb-07-01009-g005){#F5}

As streptococcal transformation efficiency is strongly dependent on donor DNA fragment size ([@B3]; [@B28]), we investigated the effect of amplicon size in the *S. mitis* system. We used unique donor DNA amplicons with a final size from 2 to 7 kb (**Figure [6A](#F6){ref-type="fig"}**). The amplicons comprised two arms of ∼0.5 to ∼3 kb, flanking a central region with an erythromycin marker. The flanking homologous arms of 1.5 kb increased transformation efficiency by approximately threefold compared to 0.5 kb arms, while further enlargement to 3.5 kb achieved an approximately sixfold increase when compared to 1 kb arms (**Figure [6B](#F6){ref-type="fig"}**). This is similar to results recently obtained in *S. mutans* ([@B28]).

![**Effect of amplicon arm size on transformation**. **(A)** Gel analysis of six amplicons of different sizes derived from the same genomic template (MI009). L, DNA ladder Gene Ruler 1kb (GenScript). **(B)** Transformation as a function of amplicon arm sizes. *S. mitis* type strain pre-culture at OD~600~ 0.5 was diluted 1:100 in C+Y~Y\ B~ and grown until OD~600~ 0.04 at 37°C in 5% CO~2~. Following, 200 μL aliquots were exposed to 300 nM of CSP, 150 ng mL^-1^ donor DNA amplicon (aRJ20, aRJ22, aRJ23, aRJ24, aRJ25, and aRJ26) and further incubated in closed tubes for 4 h at 37°C in air atmosphere. The % of CFU containing Erm^R^ transformants was determined by plating on blood plates with and without Erm. The results are averages from three replicates and representative of three independent experiments. Error bars represent standard error of the mean.](fmicb-07-01009-g006){#F6}

The Optimized Protocol Results in Transformation Efficiencies Significantly Higher Than the THB-HS Standard Protocol
--------------------------------------------------------------------------------------------------------------------

We compared the optimized protocol in C+Y~Y\ B~ with previously published protocols in THB-HS ([@B12]; [@B33]). The protocol in THB-HS consists of 1:10 dilution of pre-cultures prepared in the same medium, followed by addition of 200 nM CSP and donor DNA, and incubation for 4 h. **Figure [7](#F7){ref-type="fig"}** shows that the transformation efficiency with pVA838, a second order process, was slightly higher with the new protocol, while transformation with the aRJ20 amplicon as donor DNA resulted in 20-fold higher values, thus confirming the superiority of the optimized protocol in C+Y~Y\ B~.

![**Transformation as a function of different protocols and donor DNA types**. Following the optimized protocol, *S. mitis* type strain pre-culture at OD~600~ 0.5 was diluted 1:100 in C+Y~Y\ B~ and grown until OD~600~ 0.04 at 37°C in 5% CO~2~. Then, 200 μL aliquots were exposed to 300 nM of CSP and 150 ng mL^-1^ amplicon (aRJ20) or 1 μg replicative plasmid pVA838. Cells were further incubated in closed tubes for 3 h at 37°C air atmosphere. The % of CFU containing Erm^R^ transformants was determined by plating on blood plates with and without Erm. The results are averages from two independent experiments. Bars represent standard error of the mean. Differences in efficiency between media were analyzed by Student's *T*-test (^∗^*p* \< 0.05).](fmicb-07-01009-g007){#F7}

*S. mitis* SK321 Shows Similar Transformation Rates, but Higher *sigX* Expression than the Type Strain
------------------------------------------------------------------------------------------------------

The competence apparatus in *S. mitis* is not always intact, as suggested by a recent study showing that 5 of 15 strains had defects in either *sigX* or other competence effector genes required for transformation ([@B20]). This could be one reason why the transformation of *S. mitis* in the laboratory setting has been regarded as challenging. However, with 77% of the strains having apparently intact competence systems, it is expected that a significant range of strains will be amenable to transformation once optimal conditions are defined.

We used the improved transformation protocols for the *S. mitis* type strain presented above to test the transformation of 4 other *S. mitis* strains, using CSPs as deduced from their *comC* sequences. Among these, *S. mitis* SK321 was transformed with pVA838 at efficiencies similar to the type strain (**Figure [8A](#F8){ref-type="fig"}**), while the remaining strains were not amenable to transformation either with pVA838 or the 7 kb amplicon aRJ21 (percentage similarity of the corresponding region in the reference genomes was approximately 50%). We further constructed a *sigX* reporter in SK321 (MI092) to examine the kinetics of competence development in this strain compared to the type strain. Although *sigX* expression was significantly higher in SK321, the window of competence in the presence of CSP was similar in the two strains, with maximum levels of *sigX* expression between 15 and 30 min (**Figure [8B](#F8){ref-type="fig"}**).

![**Comparison of transformation efficiency and *sigX* expression in *S. mitis* type strain and *S. mitis* strain SK321**. **(A)** *S. mitis* type strain and SK321 pre-cultures at OD~600~ 0.5 were diluted 1:100 in C+Y~Y\ B~ and grown until OD~600~ 0.04 at 37°C in 5% CO~2~. Following, 200 μL aliquots were exposed to 300 nM of their respective strain specific CSP or kept untreated. Cells were transformed with 1 μg mL^-1^ replicative plasmid pVA838 at 37°C in air atmosphere for 3 h. The % of CFU containing Erm^R^ transformants was determined by plating on blood plates with and without Erm. The results are representative of three independent experiments. Bars represent standard error of the mean. Differences in efficiency between cultures with and without CSP were analyzed by Student's *T*-test (^∗^*p* \< 0.05). **(B)** The *sigX* reporter type strain (MI055) and SK321 (MI092) were grown in 200 μL of C+Y~Y\ B~ in a 96-well plate in air at 37°C with 300 nM of their respective strain specific CSP or kept untreated. Culture optical density (OD~600~) and *sigX* expression (RLU/OD) were monitored periodically. The results are averages from three replicates and representative of three independent experiments. Error bars represent standard error of the mean.](fmicb-07-01009-g008){#F8}

Analyses of the genomes of these strains available at the Human Oral Microbiome Database^[1](#fn01){ref-type="fn"}^ revealed that they possess homologs of all genes known to be involved in development of competence for genetic transformation in *S. pneumoniae*, but with possible truncations or mutations involving the *sigX* gene (**Table [3](#T3){ref-type="table"}**). This adds to the body of evidence indicating that some strains of *S. mitis* may not exhibit a fully functional competence apparatus ([@B20]). Furthermore, all *S. mitis* strains tested present the constitutively expressed gene *endA*, which encodes for an indispensable endonuclease involved in DNA transport.

###### 

Transformability and putative competence genes in five *S. mitis* strains.

                      Genes                   *S. mitis* strains^a^                     
  ------------------- ----------------------- ----------------------- ---- ----- ------ ------
  Transformability                            \+                      \+   \-    \-     \-
  Early genes         *comAB*                 \+                      \+   \+    \+     \+
                      *comCDE*                \+                      \+   \+    \+     \+
                      *sigX1*                 \+                      \+   ^∗^   ^∗∗^   ^∗∗^
                      *sigX2*                 \+                      \+   \-    ^∗∗^   \-
  Core SigX regulon   **Recombination**                                                 
                      *radA*                  \+                      \+   \+    \+     \+
                      *coiA*                  \+                      \+   \+    \+     \+
                      *dprA*                  \+                      \+   \+    \+     \+
                      *ssbB*                  \+                      \+   \+    \+     \+
                      *recA*                  \+                      \+   \+    \+     \+
                      *comFA-comFC*           \+                      \+   \+    \+     \+
                      *cilC*                  \+                      \+   \+    \+     \+
                      *comEA-comEC*           \+                      \+   \+    \+     \+
                      *comGA-comGG*           \+                      \+   \+    \+     \+
                      **Fratricide**                                                    
                      *cbpD*                  \+                      \+   \+    \+     \+
                      **Unknown functions**                                             
                      *dut*                   \+                      \+   \+    \+     \+
                      *rmuC, ccs50*           \+                      \+   \+    \+     \+
                      *yhaM, cbf1*            \+                      \+   \+    \+     \+
                      *yfiA*                  \+                      \+   \+    \+     \+
                      *pepF*                  \+                      \+   \+    \+     \+
                      *pilC*                  \+                      \+   \+    \+     \+
                      *radC*                  \+                      \+   \+    \+     \+
                      *cinA*                  \+                      \+   \+    \+     \+

a

Genome data used for the identification of competence genes: NCTC12261 (CCUG 31611), accession AEDX00000000; SK321, accession AEDT00000000; SK575, accession AICU00000000; SK579, accession AJJL00000000; SK616, accession AICR00000000.

∗

Substitution of two conserved N-terminal aminoacid residues (E4K; L5M).

∗∗

Lack of the 5 to 8 C-terminal aminoacid residues possibly essential for proper function of σ

X

. +Present, -- Absent

.

Application for Markerless Transformation of *S. mitis*
-------------------------------------------------------

Selective markers are often used for microbial mutagenesis, especially when transformation efficiencies are low. Despite their value, markers carry unwanted information and might interfere with gene expression or subsequent analysis. The need for multiple mutations may also lead to an accumulation of antibiotic resistance genes. With markerless mutations, it is possible to make as many genome modifications as desired, as long as the mutation is tolerated. In addition, a markerless method based on highly competent cells can be an important tool considering the wide range of possible downstream applications, such as gene knockouts, direct base mutations, promoter editing, and missense mutations. Over the years different markerless mutations strategies have been developed and most of them are based in two-step counter-selection methods ([@B6]; [@B44]; [@B9]; [@B40]). We recently described a one-step method applied in *S. mutans* ([@B28]). The high efficiency of our optimized protocol opened the possibility to apply this methodology to create a markerless deletion (69 bp) in an ORF encoding a peptide in the *S. mitis* type strain. Fragments a and b were amplified with primers FP1163/FP1164 and FP1165/FP1166. Both sections were then fused and amplified with nested primers FP1167/FP1168 creating a final donor amplicon of 5.2 kb. This amplicon (aRJ19) carried the 69 bp deletion and ∼2.6 kb flanking regions of homology with the recipient chromosome. The aRJ19 product was used directly to transform *S. mitis* type strain. Forty-four colonies from plates without antibiotics were screened with specific flanking primers for the insertion of the mutation (**Figures [9](#F9){ref-type="fig"}** and **[10](#F10){ref-type="fig"}**). Forty-one per cent of the colonies contained the mutation allele, among which only 3 colonies (6.8%) presented both the parent and the mutant alleles. Complete segregation was observed using DNA from C1 and C4 (DNA 1 and DNA 4), as well of derived colonies (2C1 and 2C4) that were grown for several generations (**Figure [11](#F11){ref-type="fig"}**). Thus, we can conclude that segregation took place already within the 3 h of DNA exposure used in the transformation assay. The summary of all variables tested in the optimization of the protocol is presented in **Figure [12](#F12){ref-type="fig"}**.

![**Workflow for markerless genome editing**. Amplicon design and construction (I to III) are prepared according to the desired mutation, exemplified in this diagram as a gene deletion (marked in red). This step is followed by a highly efficient (\>10%) method for natural transformation (IV). Two dozen colonies recovered from the transformation step are screened with specific primers that amplify fragments with different sizes in the mutant when compared to the parent (V). Isolation of colonies with only the new recombined chromosomal DNA (VI).](fmicb-07-01009-g009){#F9}

![**Gel analysis of the first PCR-screening for the markerless mutation**. Forty-four colonies were screened with pair of primers FP1169/FP1170. Fifteen colonies presented only the mutant allele (M -- 277 bp band), while three presented both parent and mutant alleles (X -- two bands). Twenty-six colonies presented only the parent allele (P -- 346 bp). Transformation efficiency was 41%. L, DNA ladder Gene Ruler 1kb plus (GenScript); DNA control, control with type strain DNA; C, colony followed by the number; M, mutant colony; P, parent strain colony; X. mixed colony presenting both parent and mutant alleles;-, DNA not detected.](fmicb-07-01009-g010){#F10}

![**Gel analysis of segregants from candidate mutant-containing clones**. Primer pair 1 (FP1169/FP1170) amplifies a 346 bp fragment in the parent and a 277 bp fragment in the mutant. Primer pair 2 (FP1171/FP1172) amplifies a 399 bp fragment in the parent but produces no band in the mutant, since primer 1171 is located in the deleted locus. DNA 1 and 4 were extracted from two pure mutant colonies retrieved from the first screening procedure (C1 and C4 in **Figure [10](#F10){ref-type="fig"}**). Colonies 1 and 4 (C1, C4) were isolated and grown from the first screening procedure for several generations in order to promote segregation of the mutant strain. L, DNA ladder Gene Ruler 1kb plus (GenScript); DNA control, control with type strain DNA; DNA, extracted DNA after the first screening followed by the colony number; 2C, tested colony after growing for several generations to allow segregation, followed by the colony number.](fmicb-07-01009-g011){#F11}

![**Summary of all variables tested in the optimization of the protocol**. Different media, culture dilution, time points of transformation, CSP concentration, type of donor DNA, and amplicon sizes were used during the optimization steps. Chosen optimal conditions are in ![](fmicb-07-01009-e001.jpg), and the methods used to assess competence are in ![](fmicb-07-01009-e002.jpg).](fmicb-07-01009-g012){#F12}

Conclusion
==========

Mechanisms of natural genetic transformation in *S. mitis* have not been thoroughly studied, leaving a gap in the knowledge about this species. As one plausible origin of this lacuna is the challenge in genetically transforming *S. mitis* in the laboratory setting. Thus, the optimized protocol we present here will facilitate future studies of this organism. Based upon the use of a semi-defined medium, specific dilution ratios, increased concentration of CSP, and a large amplicon, we increased *S. mitis* transformation efficiency by more than 3000-fold. This improvement in the protocol allows easy and direct genetic manipulation of the type strain, which also applied to strain SK321, broadening future prospects for the study of genetic transformation in the species as well as of other aspects of *S. miti*s biology.
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